Kim R Tsuchimoto Monopar Therapeutics (MNPR) insider trading activity

Kim R Tsuchimoto is Chief Financial Officer of Monopar Therapeutics. Currently has a direct ownership of 57,429 shares of MNPR, which is worth approximately $1.43 Million. The most recent transaction as insider was on Jan 01, 2022, when has been sold 1,231 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 57.4K

0% 3M change

51.18% 12M change

Total Value Held $1.43 Million

Kim R Tsuchimoto Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 01 2022	BUY Exercise of conversion of derivative security	-	1,231 Added 18.51%	5,420 Common Stock
Dec 31 2021	SELL Payment of exercise price or tax liability	$1,608 $3.21 p/Share	501 Reduced 10.68%	4,189 Common Stock
Dec 31 2021	BUY Exercise of conversion of derivative security	-	1,221 Added 20.66%	4,690 Common Stock
Sep 30 2021	SELL Payment of exercise price or tax liability	$2,060 $4.87 p/Share	423 Reduced 10.87%	3,469 Common Stock
Sep 30 2021	BUY Exercise of conversion of derivative security	-	1,221 Added 23.88%	3,892 Common Stock
Jun 30 2021	SELL Payment of exercise price or tax liability	$4,847 $5.89 p/Share	823 Reduced 23.55%	2,671 Common Stock
Jun 30 2021	BUY Exercise of conversion of derivative security	-	2,442 Added 41.14%	3,494 Common Stock
Jan 01 2021	SELL Payment of exercise price or tax liability	$3,084 $6.12 p/Share	504 Reduced 32.39%	1,052 Common Stock
Jan 01 2021	BUY Exercise of conversion of derivative security	-	1,231 Added 44.17%	1,556 Common Stock

KRT

Kim R Tsuchimoto

Chief Financial Officer

Wilmette, IL

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MNPR shares.

Notify only if

Value

Insider Trading

Get notified when an Monopar Therapeutics insider buys or sells MNPR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Monopar Therapeutics

Track Activities on MNPR

Account